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We develop a physiologically-based lattice model for the transport and metabolism of drugs in the functional unit 
of the liver, called the lobule. In contrast to  earlier studies, we have emphasized the dominant role of convection 
in well-vascularized tissue with a given structure. Estimates of convective, diffusive and reaction contributions are 
given. We have compared drug concentration levels observed exiting the lobule with their predicted detailed 
distribution inside the lobule, assuming that most often the former is accessible information while the latter is 
not. 
I. INTRODUCTION 
Pharmacokinetics aims to understand and predict behavior of various drugs through the body by studying the drug’s 
distribution, absorption, metabolism and elimination from the body.  Traditionally, such information can be 
extracted by examining drug concentration in the plasma or blood at several time points and generating a 
concentration-time curve that first rises based on the drug’s absorption rate and then declines after reaching its 
maximum value governed by the drug’s elimination rate.  The result will be used to determine optimal dosing 
regimes, potential toxicities as well as possible drug-drug interactions. 
To understand and predict drug behaviour through the body, compartmental models are commonly used in 
pharmacokinetics, Jacquez [1]. In general, each organ is represented by a compartment that contains a homogenous 
number of drug molecules undergoing a set of chemical kinetic reactions. The compartment’s input/output is 
governed by linear kinetic processes with constant rate coefficients. At the end, the whole system that may contain 
several compartments is described by coupled first order differential equations whose solutions take the form of a 
sum of terms that are exponential in time.  
Nonlinear drug-organ interactions, however, cannot be described adequately by classical compartment models. As 
observed in clinical data, the concentration-time curve shows a non-exponential time-dependency, asymptotically. 
Furthermore, observation of anomalous kinetics in the experimental data also suggests that the kinetic reactions 
should be occurring on or within fractal media with a time-dependent kinetic rate coefficients (Anacker and 
Kopelman [2], Kopelman [3]). 
To address the above shortcomings several explanations have been proposed, including a stochastic random walk 
model for the drug molecules (Wise et al [4] ), convective-diffusive transit behaviour in the liver (Norwich and Siu 
[5]), gamma-distributed drug residence time (Wise [6]), transient fractal kinetics (Anacker and Kopelman [2]), and 
fractal Michaelis-Menten kinetics (Marsh and Tuszynski [7]).  All of these studies, however, represented an organ 
as a homogenous compartment that is not realistic, i.e. physiologically-based.  
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A. Lattice Models of the Liver 
Alternatively, to take into account the organ heterogeneity and simulate enzyme kinetics in disordered media, 
lattice models have been introduced by investigators.  Berry [8] performed Monte Carlo simulations of a Michaelis-
Menten reaction on a two-dimensional lattice with a varying density of obstacles to silate the barriers to diffusion 
caused by biological membranes. He found that fractal kinetics resulted at high obstacle concentrations. Kosmidis 
et. al [9] performed Monte Carlo simulations of a Michaelis-Menten enzymatic reaction on a two-dimensional 
percolation lattice at criticality. They found that fractal kinetics emerged at large times. 
Previously [10], we developed a network model of the liver consisting of a square lattice of vascular bonds 
connecting two types of sites that represent either sinusoids or hepatocytes. Random walkers explored the lattice at 
a constant velocity and were removed with a set probability from hepatocyte sites. To simulate different 
pathological states of the liver, random sinusoid or hepatocyte sites were removed. For a lattice with regular 
geometry, it was found that the number of walkers decayed according to an exponential relationship. For a 
percolation lattice with a fraction p of the bonds removed, the decay was found to be exponential for high trap 
concentrations but transitioned to a stretched exponential at low trap concentrations. 
The models described above are all basic random walk models, and the lattices are abstract representations of the 
geometry of the space. The objective of this paper is to develop a lattice model that incorporates realistic 
anatomical and physiological properties of the liver as well as the flow of blood with reacting tracers 
In this paper, we introduce a physiologically-based lattice model of the functional unit of the liver that takes into 
account parameters such as the distribution volume, permeability, and porosity of the liver vasculature and cells. 
Instead of simple random walkers, a blood-like fluid containing drug molecules flows through the vascular space of 
the lattice. This model takes into account flow-limited and diffusion-limited exchange of drug molecules into the 
extravascular space from the sinusoids; sequestration of the drug molecules within liver cells with enzymatic 
transformation; and exchange of the metabolized drug molecules back from liver cells to the vasculature. Estimates 
and consequences of the competing flow processes are given. Furthermore, the enzymatic transformation of the 
drug can be either simple or saturable. The model allows us to include the effects of the intrahepatic mixing process 
on the enzymatic transformation of drug molecules. 
II. THE LIVER AND DRUG KINETICS 
A. Liver Architecture 
At the macroscopic level, the liver consists of three vascular trees, two supply trees that originate from the portal 
artery and hepatic vein, and one collecting tree that drains into the portal vein [11]. The vessels bifurcate down to 
the terminal arterioles and venules, which are organized into portal tracts along with a terminal bile duct. Liver 
cells, called hepatocytes, radiate outward from the terminal vessels. These plates of hepatocytes are interspersed by 
sinusoids, which play the role of the capillary in the liver, and the spaces of Disse, which are the extravascular 
space of the liver [12]. Finally, the blood is collected and removed by the hepatic venules. 
B. Functional Unit 
The functional unit of an organ is the smallest structural unit that can independently serve all of the organ's 
functions [13]. Because of its complexity, there is continued debate about what the functional unit of the liver 
should be. The classic lobule is a hexagonal cylinder, centered around a hepatic venule and with portal tracts 
situated at the corners. The portal lobule has a similar shape but is centered about a portal tract with the hepatic 
venules at the periphery [14]. The acinus is another proposed unit and is based on the pattern formed by the cords 
of hepatocytes between two central venules. Matsumoto and Kawakami [15] suggested that the classic lobule can 
be divided into primary lobules, which are cone-shaped and each fed by one portal tract and drained by one hepatic 
venule. Teutsch and colleagues [16, 17] performed a morphological study of rat and human liver lobules, and their 
results support the idea of a secondary unit made up of primary units in what they term as a modular architecture. 
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They conclude, however, that the primary unit is more polyhedral in shape than conical. Other experiments done by 
Ruijter et al. [18] suggest that the primary unit is needle-shaped and that there are equal amounts of portal and 
central vein associated with one unit. For this study, the primary unit is taken to be one-fourth of the classical 
lobule. The relevant anatomical values are listed in Table I. 
C. Elimination Kinetics 
Here drug uptake and elimination (i.e. conversion to metabolized product) is viewed as a single-step saturable 
process following Michaelis-Menten kinetics [19], such that 
 
( ) ( ) ( )( )tCK/tCv
dt
tdC
mmax +=                                                                                     (1) 
Here C(t) is the local drug concentration and ( )
dt
tdC is the drug metabolization rate. (In what follows, C(t) is 
expressed as ρxi with ρ the fluid density and xi mole fractions of i-th species).  Note we are explicitly modeling the 
drug transport to an individual hepatocyte surface via our lobule lattice model and assume an effective one-step 
reaction transformation beyond that point. We recognize that drug incorporation and elimination is still a multi-step 
process even once the drug reaches the cell surface however. It is hoped that these approximations ignore processes 
occurring on a shorter time scale than the experimental resolution. Nonetheless, we explore possible complications 
via simple sensitivities to the choice of reaction time constant. 
III. MODEL AND METHOD 
The primary unit of the liver was approximated by a symmetry element of a 51 x 51 square lattice such that four 
units make up one lobule. The architecture of the lattice consists of hepatocyte grid cells interlaced by a network of 
narrower sinusoidal grid cells (Figure 1). The diameter of the sinusoid grid cells was taken to be 0.0006 cm, and the 
diameter of the hepatocyte grid cells was taken to be 0.0024 cm. The length of the lattice is thus 0.0750 cm per 
side. Doubling this value gives a lobule diameter of 0.150 cm, which is consistent with values listed in Table I. 
Convective molar flux is modelled according to Darcy's Law [20]: 
 pKxvxJ kkiki
c
ik ∇µ
ρ=ρ=                                                                                          (2) 
where Jcik is the i-th component of  fluid flux in k-direction, ρ and µ are fluid molar density and viscosity, vk , Kk  
and ∇kp are the Darcy velocity, permeability, and pressure gradient in direction k, respectively. The blood viscosity 
µ is taken to be 3.5 mPa-s (3.5 centipoise).  Blood molar density is assumed  that of water, ρ at 55.4 moles/cm3. It is 
emphasized that in this paper, following Darcy’s Law and the conventions of flow in porous media, permeability K 
is defined as a measure of the transmissibility of a grid cell to the flow of a fluid, and is expressed in units of area 
(e.g. cm2). 
Each sinusoid grid cell represents a tubular vessel of diameter 2a. Taking the ratio of the volume of the vessel to the 
volume of the grid cell yields a porosity of  
 7854.0
4a
aa
3
2
sin =
pi
=
pi
=φ                                                                                          (3) 
For a cylindrical tube, the permeability can be calculated from the tube radius [13] 
 
2
2
sin micron126.18
aK ==                                                                                       (4) 
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Here and in what follows, it is noted that porosity is dimensionless while permeability has units of a characteristic 
length squared.  
Each parenchymal grid cell represents a cellular (hepatocyte) component and an extracellular (space of Disse) 
component. A ratio of 0.75 to 0.25 was chosen for their respective contributions to the volume, and the porosity of 
the parenchymal sites was therefore 0.25. 
The corresponding permeability of the tissue grid cells is estimated from a Carmen-Kozeny model [20] of flow 
around a spherical object (the hepatocyte) of radius 12 microns. This states the permeability is proportional to the 
object's diameter Dp and the porosity φtis as follows: 
 ( )2
32
1 180 tis
tisp
tis
D
K φ
φ
−
=                                                                                                    (5) 
An ideal result where Dp/L=1 or R/L=0.5 with L as grid size and R as particle radius gives  
 ( ) ( ) 4764.0or5236.0
3
5.041 tis
3
tis =φ=pi=φ−                                                            (6) 
Then assuming as we do, L = Dp= 24 microns, the Carmen-Kozeny formula yields 
 
2
tis micron262.1K =  
The Carman-Kozeny expression basically states physically that the order of magnitude of the permeability scales 
with the particle size squared.  
The above analysis is an ideal result as the ECM around the cell particle will further reduce porosity. Thus we could 
study a range of tissue effective porosities, leading to a range of effective tissue permeabilities. Table II summarizes 
a range of possible values. In this paper, we will utilize the “base case” value for tissue porosity and permeability, 
while the effects of more extreme choices will be examined in a second paper. 
The convective driving force originates from an input site corresponding to a terminal portal venule at one corner of 
the lattice and an output site corresponding to a terminal hepatic venule at the opposite corner. For simplicity, the 
hepatic artery blood supply, which is lower in volume and pulsatile in nature, is omitted for the current simulations. 
The pressure value at the inlet and the outlet are taken to be Pin = 103 kPa and  Pout = 101.8 kPa, respectively. After 
subtracting the atmospheric pressure, these values are consistent with experimental values quoted by Rappaport [21], 
who found that the terminal portal venule pressure was in the range 0.59 kPa to 2.45 kPa and that the terminal hepatic 
venule pressure was 0.49 kPa. As we shall demonstrate, this applied pressure differential results in a convective flow 
level that is determined primarily by the effective permeability of the lobule. Thus various liver damage scenarios can 
be expected to affect this flow. This aspect of the modelling is of practical importance and will be explored in more 
detail in a separate publication. 
For multicomponent flow, the model tracks the compositions (molar or mass fractions) of all components in the 
fluid. In addition to convective transport a diffusive flux contribution of 
 ( )ikikdik xDJ ρ∇=                                                                                                         (7) 
is considered with Jdik being the molar diffusive flux and Dik the diffusion constant of species i in direction k. The 
estimated diffusion constant in all directions used here is based on a molecular weight rescaling of glucose 
diffusion. Here 
 ( )
sec
101.7
2
10 mGLCD −×=                                                                                         (8) 
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With a cubic root of the molecular weight ratio of glucose to PAC used as conversion factor (Factor = (180/854)0.33 
= (1/4.74)0.33 = 1/1.68), an estimated effective diffusion constant for PAC is  
 ( )
sec
102.4
68.1
101.7 21010 mPACD −
−
×=
×
=                                                                    (9) 
Tissue effective diffusion value should be less, here we employ an order of magnitude reduction in the value of D 
 ( )
sec
102.4
68.1
101.7 21111 mPACD −
−
×=
×
=                                                                    (10) 
Effective diffusion constants for PAC-OH are assumed identical to PAC values. These values are converted to the 
simulation units of cm2/min and also summarized in Table II. 
The drug paclitaxel was used as a reactive tracer, and its Phase I metabolism was modeled using the general 
formula of one paclitaxel (PAC) molecule being transformed into the metabolite 6ff -hydroxypaclitaxel (PAC-OH) 
by the cytochrome P450 (CYP) isozyme CYP2C8 [22]. 
 PAC + CYP   >  PAC-OH + CYP                                                                             (11) 
The enzyme only exists in grid cells containing hepatocytes so all reaction is localized in these sites. In this paper, 
saturable Michaelis-Menten kinetics are assumed, defined by a maximum rate vmax (in units of molar fraction/min) 
and a half saturation value KM (in units of molar fraction).  This reaction proceeds in a linear manner at a rate 
characterized by k = vmax/Km (in units of min-1) when injection concentrations are much below the half saturation 
value. 
Reaction parameter values are based on the work of Vaclavikova et al [23] who measured directly PAC conversion 
to PAC-OH kinetics without any tissue distribution issues and uptake by the cell itself, as they use microsomes 
directly as the source of CYP.  As such, any bottlenecks associated with drug uptake should imply that reaction 
rates would be slower than those based on parameters values given by Vaclakova et al [23]. We are modeling tissue 
distribution effects separately based on our lobule model. Table III summarizes the reaction parameters. 
The simulations were performed using the STARS advanced process simulator designed by the Computer Modelling 
Group (CMG) Ltd. in Calgary, Alberta, to model the flow and reactions of multiphase, multicomponent fluids through 
porous media [24], [25], [26]. Additionally, STARS has earlier been used to model reactive flow processes in cortical 
bone [27], [28], [29], [30] as well as through the intervertabral disk [31]. 
IV. RESULTS 
Non-reactive Flow Characteristics 
As discussed above, flow is induced on the regular lattice of Figure 1 by applying a pressure difference across the 
inlet and outlet points. With the chosen lobule flow parameters for porosity, permeability, and blood viscosity, this 
translates to a steady flow rate 2.1 cm3/min as illustrated in Figure 2. A short timescale of about 2.0x10-5 min 
needed to establish this pressure gradient is also illustrated in this figure by expanding the time axis. Figure 3 
demonstrates the steady state velocity profile throughout the lattice, illustrating both the diverging/converging 
nature of the flow near the inlet and outlet points, as well as the orders of magnitude difference of the flows in the 
sinusoids and tissues, respectively. (This plot uses a logarithmic colour scale axis). 
When blood with a relative composition of 1 micro-gram paclitaxel (1.8 x10-8 mole fraction) is infused into the 
lattice assuming nonreactive hepatocytes, the time required to traverse the lattice is approximately 1 min as 
demonstrated in Figure 4. This production profile is convective flow dominated as the addition of diffusion 
minimally alters the production profile.  
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The evolution of the paclitaxel concentration on the lattice followed a spatially homogeneous progression (Figure 
5), which shows the increasing levels of injected drug after 0.01 min and 0.14 min. By 0.14 min, paclitaxel is being 
seen at the outlet of the lobule. After 0.5 min, paclitaxel completely covers the lattice (not shown). 
If the diffusive flow contribution is removed, however, the paclitaxel profiles on the lattice are significantly different.  
As is also illustrated in Figure 5, again at 0.01 min and 0.14 min, a distinct two-scale behavior is noted, whereby the 
sinusoids are first infused with the drug, and only at later times do the drug levels in the tissue approach injected 
concentration levels. This behavior reflects the convective levels of flow in the sinusoids and tissues noted earlier 
(Figure 3). A further comparison of Figure 5 cases reveals that the sinusoid drug concentration levels in the two cases 
are similar, however, explaining the similar drug production characteristics note in Figure 4, as paclitaxel is produced 
directly from the sinusoids. 
Base Case Reactive Flows 
The effects of paclitaxel drug metabolism by hepatocytes are next considered. Here the base case reaction 
parameters of Table III are employed, and the same injected paclitaxel injected concentration (1.8e-8 mole fraction) 
is considered. With the employed reaction half saturation constant value of 1.8 x10-7 mole fraction, this injection 
level implies the Michaelis-Menten model reduces to a linear reaction scheme. 
Figure 6 illustrates injected drug and produced drug and metabolite production for this case. Essentially at this 
reaction rate, all injected paclitaxel is converted to metabolite by the lobule hepatocytes. The production profile of 
PAC-OH here is identical to the production profile of PAC in the non-reaction case, as shown in Figure 4.  Figure 7 
shows the PAC and PAC-OH profiles across the lobule lattice at 0.01 min, 0.14 min, and 0.50 min, respectively. 
The PAC concentrations in the sinusoids and the PAC-OH concentrations in the tissue are equivalent to the PAC 
concentrations in both sinusoids and tissue for the non-reacted case (Figure 5). Figure 7 also shows most clearly 
there is an inlet distance over which the reaction conversion time is not fast enough to convert the injected 
paclitaxel. 
Figure 8 illustrates injected drug and produced drug and metabolite production for the same case except that 
diffusive transport has been removed. In contrast to Figure 6 with diffusion, there is now only a limited amount of 
conversion of PAC to PAC-OH even at long times. The PAC and PAC-OH profiles at various times (0.01 min, 0.14 
min, and 0.50 min) as shown in Figure 9, confirm this behavior where it is shown that the PAC concentration in the 
sinusoids propagates throughout the lobule, while the PAC-OH concentrations in the tissue increase less rapidly 
and up to a lower level. 
Reactive Flow Sensitivities 
In this section, the consequences of the chosen reaction parameters are illustrated. Figure 10 shows production 
behavior with a 100-fold reduction in maximum reaction rate and with diffusion effects included. The small level of 
produced PAC indicates that reaction rates must be reduced to about this level before any significant change in drug 
production behavior can be expected. Drug distribution in the lobule for this case is shown in Figure 11 for the 
times 0.01 min, 0.14 min, and 0.50 min.  This figure should be contrasted with Figure 9. Here the early time results 
and upstream results for PAC distributions at longer times are quite different, reflecting the reduced reaction rate. 
However, the later time and downstream results for PAC-OH distribution resemble quite closely the faster reaction 
limit. Here the propagation time across the lobule gives enough time to compensate for changes in reaction rate. In 
summary, reaction rates larger than the base case or even 10-fold reduction from base case can be expected to 
produce very similar drug production behavior and differences only in the inlet region of the lobule are to be 
envisioned. 
In contrast, once a critical time-scale is crossed, much more significant changes in drug distribution behavior can be 
expected, both internally throughout the lobule and in terms of produced profiles. Figure 12 shows drug metabolite 
production behavior with a 1000-fold reduced metabolic rate, and including diffusive mixing. Here almost equal 
levels of PAC and PAC-OH are seen exiting the lobule. At 0.01 min almost no PAC-OH is converted in the lobule 
at this rate (see Figure 13), while at later times (0.14 min and 0.50 min), converted PAC-OH starts to be seen at the 
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outlet regions at levels similar to PAC. Essentially, the inlet region behavior occurring at faster reaction rates now 
covers the whole lobule region. 
Finally, sensitivities to injected PAC concentrations were explored, utilizing injection concentrations of 1.8 x10-7 
and 1.8 x10-6 mole fractions (i.e. clearly above that of the base case 1.8 x10-8). In these runs, the base case reaction 
parameters were maintained. In particular, the half saturation value of 1.8 x10-7 was employed, indicating that the 
linear, intermediate, and saturation levels of the Michaelis-Menten expression were being probed with the three 
injected concentration levels. As illustrated in Figure 14 for the runs without diffusion, the production profiles of 
PAC-OH remained unchanged for each case, as long as the production maxima were rescaled to the corresponding 
injection concentrations. Apparently, with fast reaction rates, the Michaelis-Menten form had little impact on 
production behavior. 
V. ANALYSIS 
The results we have presented can be rationalized by a comparison of process timescales.  
Calculation of breakthrough times can be based on two concepts: either only the sinusoids are accessible or the 
whole lobule (tissue+sinusoid) is accessible to injected species. The sinusoid pore volume in our element is 4.77 
x10-7 cm3 while the complete lobule element volume is 7.344 x10-7 cm3.  Because the steady state flow rate in our 
model is 2.44 x10-6 cm3/min (see Figure 2), this means the breakthrough time is 4.77/24.4 = 0.20 min for just 
sinusoid accessibility and 7.34/24.4 = 0.30 min for the whole lobule-sampled space. These should be viewed as two 
limiting vertical lines on the time history plots as two ideal limits without any diffusion or mixing effects (physical 
or numerical). It is noted for example that our time history plot of PAC production with no reaction and with or 
without physical diffusion (see Figure 4) has a produced concentration of 0.9 x10-8 (i.e. half of the injected 1.8 x10-8 
concentration) at 0.19 min, about what is expected. The main point here is that most of the production behavior 
differences for our various cases should lie between these two ideal "half-value" limits. 
The next timescale is governed by a “pressure diffusion” coefficient 
 
eff
p
pres C
KD φµ=                                                                                                        (12) 
Here Cpeff is an effective compressibility accounting for both fluid and tissue structure effects. Fluid (water 
compressibility) is of the order of 5e-7 kPa-1. For liver (soft tissue) structural compressibility, we have chosen 1.8 
x10-5 kPa-1. Using these choices and the base case parameters of this study from Table II, we obtain 
 
min
105.1
2
4 cmDpres
+×=                                                                                         (13) 
This parameter essentially describes the time taken for pressure to come to a steady state distribution as follows. 
Utilizing a characteristic distance d = 0.15 cm (the lobule element size for the pressure calculation), this time is then 
 min 105.1 5
2
−×==
pres
pres D
dT                                                                             (14) 
Figure 2 also illustrates this characteristic time. This timescale is essentially a function of fluid properties and 
lobule structure (through  φ and K). If we were to consider pulsatile flow effects caused by hepatic artery inflow, 
this timescale would be much more important to the general process description and a more precise definition of 
compressibility might be warranted. For the present, these numbers just indicate that steady state pressure is 
achieved more quickly than other process effects. 
The third timescale is determined by particle diffusion. Here we have chosen diffusion constants based on 
paclitaxel size and simple estimates of tortuosity. The parameter choices used here are Dsin = 2.5 x10-4 cm2/min and 
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Dtis = 2.5 x10-5 cm2/min. Again with a choice of characteristic distance d = 10 micron = 1 x10-4 cm, the times 
required for particles to diffuse are 
 ( ) min 100.4
3
sin
2
sin
−×==
D
dTdiff                                                                         (15) 
 ( ) min 100.4
4
2
−×==
tis
tisdiff D
dT                                                                           (16) 
Our diffusion values should be viewed as highly optimistic. In particular, pactlitaxel is normally not molecularly 
dissolved, but rather it is some type of micellar complex with Cremophor EL surfactant, so the effective diffusion 
coefficient for this complex is probably one or more orders of magnitude smaller than what has been estimated. 
Thus the limits of diffusion and non-diffusion cases are meaningful extremes of what might be expected, for small 
molecules and large nanoparticles, respectively. 
The final timescale is reaction rate. The base limiting reaction rate 6 x10-3 min-1 converts to a reaction time 
(reaction half-life) of  
 
( )
min100.1
106
5.0ln 2
3
+
−
×=
×
=reacT                                                                        (17) 
This is essentially seen as instantaneous compared to the other timescales considered. Reducing this basic reaction 
rate by a factor of 100 or 1000  causes the reaction process to be more similar to the other timescales and different 
production profiles of PAC and PAC-OH result, as has been shown. 
Table IV summarizes the relevant assumed timescales. 
VI. CONCLUSION 
In pharmacokinetics, lattice models are introduced to address the non-heterogeneity of the organs on the drug 
distribution that has a significant impact on drug propagation throughout the body as shown by analysis of clinical 
data. 
Here we utilize the interpretation of the liver as an ensemble of islands of metabolic activity and focus on the liver 
lobule itself.   In contrast to most earlier studies that assumed that drug molecules only randomly propagate through 
the system, we have emphasized the dominant role of convection in well-vascularized tissue with a given structure. 
We have utilized an idealized representation to analyze the factors affecting drug propagation and metabolism. The 
lobule is divided into hepatocyte cells that are interlaced with narrower sinusiodal grid cells. These cells are 
connected by constant permeability throughout the entire system.  The drug molecules convectively flow through 
the sinusoidal along with blood (water here) and diffuse to the hepatocyte where metabolisms are taking place.  A 
sensitivity analysis of convective, diffusive and reaction parameters is performed and estimates of their 
contributions are presented.   We have compared the drug concentration levels observed exiting the lobule with 
their predicted detailed distribution inside the lobule, assuming that most often the former is accessible information 
while the latter is not. 
This is the first paper of series of papers on physiologically-based lattice models for liver. In this paper, we consider 
an idealized lobule lattice in order to understand the basic functionality of the unit and underlying mechanisms 
through simulations and also to set a basis for future studies.  A following paper will expand the analysis to include 
sensitivities associated with variations in lobule structure, which could reflect extents of liver damage. 
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TABLES: 
TABLE I: Anatomical Parameter Values for the Liver [11], [12] 
Parameter Value 
Hepatocyte diameter 12-24 µm 
Diameter of liver cell sheets 25 µm 
Lobule diameter 1 - 2.5 mm 
Mean sinusoid diameter 7.3 µm 
Vascular tissue component 28 - 30% 
Specific gravity of liver 1.05 
Liver volume 1071 ± 228 cm3 
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TABLE II: Lobule Regular Lattice Flow Parameters 
Parameter Characteristic Unit STARS Unit 
Sinusoid Grid Cell Size 6 micron 0.0006 cm 
Sinusoid Porosity 0.7854 0.7854 
Sinusoid Permeability 1.125 micron2 1.140 Darcy 
Sinusoid Effective Diffusion 4.2e-10 m2/sec 2.5 x10-4 cm2/min 
Tissue Grid Cell Size 24 micron 0.0024 cm 
Tissue Porosity (Ideal) 0.4764 0.4764 
Tissue Permeability (Ideal) 1.230 micron2 1.246 Darcy 
Tissue Porosity (Base) 0.2382 0.2382 
Tissue Permeability (Base) 7.35 x10-2 micron2 7.45x10-2Darcy 
Tissue Porosity (ECM) 0.1191 0.1192 
Tissue Permeability (ECM) 6.883 x10-2 micron2 6.97 x10-2 Darcy 
Tissue Effective Diffusion 4.2 x10-11 m2/sec 2.5 x10-5 cm2/min 
(1 Darcy = 0.9869 microns**2 in engineering permeability units). 
 
TABLE III: Paclitaxel Kinetic Elimination Michaelis-Menten Parameters (converted* from Vaclavikova et al, their 
Table 4) 
Parameter Characteristic Unit STARS Unit 
Maximum Rate Vmax 0.06 micronM/min 1.08 x10-9 molefrac/min 
Half Saturation Constant Km 10.0 micronM 1.8 x10-7molfrac 
Linear Rate Vmax/Km 6.0e min-1 6.0 x10-3 min-1 
*Their Table 4 quotes Vmax = 61 picomol/mg_protein/min. Using their microsomal 
protein concentration of 1 mg/ml, these numbers convert to Vmax = 0.06 micronM/min. 
 
TABLE IV: Assumed Lobule Process Time Constants 
Process Time 
Convective Transit Time (sinusoid network only) 0.200 min 
Pressure Relaxation Time Constant (in sinusoids) 1.5 x10-5 min 
Diffusion Relaxation Time Constant (CYP/CYP-OH in sinusoids) 4.0 x10-3 min 
Diffusion Relaxation Time Constant (CYP/CYP-OH in tissue) 4..0 x10-4 min 
Base Case Metabolic Uptake/Elimination Time Constant 1.0 x10+2 min 
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FIGURES 
 
 
 
Figure 1:  Homogeneous lattice. The high porosity bands represent sinusoids and the lower porosity regions 
represent tissue containing hepatocytes. 
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Figure 2: (a) Steady state flow across the lobule, (b) Short time flow transients. 
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Figure 3: Steady state velocity profile across the lobule. 
 
 
 
Figure 4: Non-reactive PAC drug propagation across the lobule, with and without diffusion effects. 
15 
 
 
(a) 
 
 
(b) 
 
(c) 
 
(d) 
 
Figure 5: Non-reactive PAC profiles across the lobule (a) at 0.01 min, with diffusion effect, (b) at 0.14 min, with 
diffusion effect, (c) at 0.01 min, no diffusion effect, (d) at 0.14 min, no diffusion effect. 
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Figure 6: Reactive PAC and PAC-OH drug propagation across the lobule, with diffusion effects and base case 
metabolism. 
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Figure 7: Reactive PAC and PAC-OH profiles across the lobule with diffusion effects and base case metabolism 
(a) PAC at 0.01 min, (b) PAC at 0.14 min, (c) PAC at 0.50 min, (d) PAC-OH at 0.01 min, (e) PAC-OH at 0.14 min, (f) 
PAC-OH at 0.50 min. 
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Figure 8: Reactive PAC and PAC-OH drug propagation across the lobule, without diffusion effects and base case 
metabolism. 
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Figure 9: Reactive PAC and PAC-OH profiles across the lobule without diffusion effects and base case 
metabolism (a) PAC at 0.01 min, (b) PAC at 0.14 min, (c) PAC at 0.50 min, (d) PAC-OH at 0.01 min, (e) PAC-OH at 
0.14 min, (f) PAC-OH at 0.50 min. 
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Figure 10: Reactive PAC and PAC-OH drug propagation across the lobule, with diffusion effects and 100-fold 
reduced metabolism. 
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Figure 11: Reactive PAC and PAC-OH profiles across the lobule with diffusion effects and 100-fold reduced 
metabolism (a) PAC at 0.01 min, (b) PAC at 0.14 min, (c) PAC at 0.50 min, (d) PAC-OH at 0.01 min, (e) PAC-OH at 
0.14 min, (f) PAC-OH at 0.50 min. 
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Figure 12: Reactive PAC and PAC-OH drug propagation across the lobule, with diffusion effects and 1000-fold 
reduced metabolism. 
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Figure 13: Reactive PAC and PAC-OH profiles across the lobule with diffusion effects and 1000-fold reduced 
metabolism (a) PAC at 0.01 min, (b) PAC at 0.14 min, (c) PAC at 0.50 min, (d) PAC-OH at 0.01 min, (e) PAC-OH at 
0.14 min, (f) PAC-OH at 0.50 min. 
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Figure 14: PAC-OH metabolite production levels from various injected PAC concentrations. 
 
